Table 2 Treatment information during hospitalization (no missing data)
Multi-center cohort data | Administrative cohort data | |||||
|---|---|---|---|---|---|---|
Variable | Overall (n = 153) | Early tapering group (n = 87) | Non-early tapering group (n = 66) | Overall (n = 229) | Early tapering group (n = 87) | Non-early tapering group (n = 142) |
Steroid pulse therapy | 119 (78%) | 70 (80%) | 49 (74%) | 117 (51%) | 54 (62%) | 63 (44%) |
Dose of steroid (low/moderate/high) | 26 (17%)/ 66 (43%)/ 61 (40%) | 9 (10%)/38 (44%)/ 40 (46%) | 17 (26%)/28 (42%)/ 21 (32%) | 73 (32%)/ 68 (30%) / 88 (38%) | 10 (11%) / 27 (31%)/ 50 (57%) | 63 (44%)/ 41 (29%)/ 38 (27%) |
Immunosuppressant | 22 (14%) | 9 (10%) | 13 (20%) | 31 (14%) | 17 (20%) | 14 (10%) |
β-lactam combination | 90 (59%) | 52 (60%) | 38 (58%) | 114 (50%) | 45 (52%) | 69 (49%) |
Macrolide | 81 (53%) | 49 (56%) | 32 (48%) | 16 (7%) | 8 (9%) | 8 (6%) |
Fluoroquinolone | 4 (3%) | 4 (5%) | 0 (0%) | 39 (17%) | 16 (18%) | 23 (16%) |
ST | 69 (45%) | 41 (47%) | 28 (42%) | 98 (43%) | 36 (41%) | 62 (44%) |
rTM | 5 (3%) | 5 (6%) | 0 (0%) | 1 (0%) | 0 (0%) | 1 (1%) |
PMX-DHP | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Mechanical ventilation | 43 (28%) | 22 (25%) | 21 (32%) | 6 (3%) | 3 (3%) | 3 (2%) |
IPPV | 12 (8%) | 7 (8%) | 5 (8%) | NA | NA | NA |
NPPV | 34 (22%) | 17 (20%) | 17 (26%) | NA | NA | NA |
HFNC | 42 (27%) | 27 (31%) | 15 (23%) | NA | NA | NA |
DNI | 89 (58%) | 42 (48%) | 47 (71%) | NA | NA | NA |